OnKure Therapeutics
PublicOnKure Therapeutics is now publicly traded
The data on this page reflects OnKure Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Oct 4, 2024
Est. Valuation at Exit
$305.16M
Total Funding Raised
$181M
Company Overview
OnKure Therapeutics is a biopharmaceutical company dedicated to discovering and developing advanced precision medicines that target validated cancer drivers, addressing unmet needs in current therapies.
Sector
Biotech
AI Layer
Non-AI
Keywords
OnKure Therapeutics Comparables
Compare OnKure Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eli Lilly and Company | 54% | |
| Vaderis Therapeutics | 40% |
OnKure Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Oct 4, 2024 | ||||
| Series C | Mar 31, 2023 | ||||
| Series B | Mar 3, 2021 | ||||
| Series A | May 2, 2018 |
OnKure Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Perceptive Advisors | Series B, Private Placement, Series C |
| Deep Track Capital | Private Placement, Series C |
| Vestal Point Capital | Private Placement |
| Delian Capital | Series A |
| Acorn Bioventures | Private Placement, Series C, Series B |
| Citadel | Private Placement, Series C, Series B |
| Samsara BioCapital | Series B, Private Placement, Series C |
OnKure Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access